Nuvation Bio execs to discuss oncology pipeline at Jefferies Global Healthcare Conference

Nuvation Bio Inc., a global oncology company, announced that its CEO David Hung and CFO Philippe Sauvage will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026. The discussion will focus on the company's efforts to develop innovative cancer treatments, including their pipeline drugs like taletrectinib and safusidenib. The event will be webcast live and available for replay for 90 days. This presentation offers investors insight into Nuvation Bio's strategy and progress in tackling difficult cancer challenges.

Nuvation Bio Inc. has a market cap of $1.54 billion and an enterprise value of $1.17 billion as of November 11, 2026, 04:02 WIB. The stock is trading at USD 4.24 on Pluang, down 2.64% in the past day, with a volume of 5,326,427 shares. This trading activity reflects ongoing investor interest as the company prepares to present at the Jefferies Global Healthcare Conference.